Grants per year
Grants 2005 2021
- 1 - 25 out of 44 results
- Status, start date (descending)
Active
Acute Liver Failure Study Group 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure
University of Texas Southwestern Medical Center at Dallas, National Institute of Diabetes, Digestive and Kidney Diseases
2/19/16 → 8/31/20
Project: Research project
Breath Tests
Acute Liver Failure
Time Management
Registries
Clinical Trials
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) -- A Multi-Center Group to Study Acute Liver Failure
University of Texas Southwestern Medical School, National Institute of Diabetes, Digestive and Kidney Diseases
9/18/15 → 8/31/19
Project: Research project
Acute Liver Failure
Safety
Liver
Wounds and Injuries
Therapeutics
A Multi-Center Group to Study Acute Liver Failure
University of Texas Southwestern Medical Center at Dallas, National Institute of Diabetes, Digestive and Kidney Diseases
9/16/15 → 8/31/20
Project: Research project
Acute Liver Failure
Hematologic Diseases
Liver
Sepsis
Viruses
Finished
Frailty and Functional Status in Older Liver Transplant Patients
University of California, San Francisco, National Institute on Aging
9/15/18 → 4/30/19
Project: Research project
Transplants
Liver
Mortality
Decision Support Techniques
Liver Transplantation
Prot # ROF-NASH_205: A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis
Ganger, D. R., Green, R., Kulik, L. M. & Rinella, M. E.
Quintiles, Inc., Takeda Development Center Americas, Inc.
2/11/14 → 2/11/17
Project: Research project
RFHE4043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rifaximin 550 mg in Subjects with Severe Hepatic Impairment and Overt Hepatic Encephalopathy
Valeant Pharmaceuticals North America LLC, Salix Pharmaceuticals, Inc.
3/12/13 → 12/31/15
Project: Research project
Prot # GS-US-337-0109: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV I
PRA Health Sciences, Gilead Sciences, Inc.
1/4/13 → 1/4/17
Project: Research project
Prot # GS-US-337-0102: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavarin for 12 and 24 Weeks in Treatment-Naive Subjects with Chronic Genotype 1 HCV Infecti
PRA Health Sciences, Gilead Sciences, Inc.
10/5/12 → 10/5/15
Project: Research project
Adduct Dipstick for Diagnosis of Acetaminophen Toxicity
Arkansas Children's Hospital Research Institute, National Institute of Diabetes, Digestive and Kidney Diseases
7/1/12 → 6/30/15
Project: Research project
Acetaminophen
Acute Liver Failure
Research
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
High Pressure Liquid Chromatography
Prot# GX-US-174-0172: Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Trans
PRA Health Sciences, Gilead Sciences, Inc.
3/19/12 → 3/19/18
Project: Research project
Prot# VX11-222-106: A Multicenter, Randomized, Double-blind, Placebo- Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subje
Parexel, Vertex Pharmaceuticals Incorporated
3/15/12 → 3/15/16
Project: Research project
Prot # VX11-950-114: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype
Parexel, Vertex Pharmaceuticals Incorporated
3/8/12 → 3/8/16
Project: Research project
Prot# VX11-950-116: An Open-Label, Phase 4 study of Telaprevir, Peginterferon Alfa-2a(Pegasys), and Ribavirin(Copegus) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not
Parexel, Vertex Pharmaceuticals Incorporated
3/8/12 → 3/8/16
Project: Research project